AI Article Synopsis
- Polymorphisms in matrix metalloproteinases (MMPs), specifically MMP1 and MMP3, are linked to Alzheimer's and Parkinson's diseases, with MMP1 and MMP3 levels elevated in affected brain tissues.
- A study involving 97 Alzheimer's and 52 Parkinson's patients, along with 101 controls, examined the relationship between MMP1 and MMP3 genetic variations and disease risk.
- Results indicated a significant interaction between the MMP3*5A polymorphism and APOE 4 allele, markedly increasing Alzheimer's risk, suggesting that MMP3 might play a role in disease development.
Article Abstract
Polymorphisms affecting the expression of matrix metalloproteinases (MMPs), i.e. proteolytic enzymes that degrade intercellular material, have been found at position -1607 (1G/2G) in MMP1 and at -1171 (5A/6A) in MMP3. Interestingly, elevated levels of MMP1 and MMP3 have been observed in the brains of Alzheimer's disease (AD) patients and those of tissue inhibitors of MMPs in the cerebrospinal fluid of AD and Parkinson's disease (PD) patients, suggesting a role for MMPs in these disorders. The aim was to investigate a possible association between the afore-mentioned MMP1 and MMP3 polymorphisms and the risk of developing AD or PD. The polymorphisms were genotyped in 97 AD, 52 PD and 101 control patients. We found an interaction between MMP3*5A and APOE 4 alleles (P < 0.0001) which increases the risk of AD (OR: 23.7, 95% CI: 5.8-144.9, P < 0.0001) compared to those who possess neither MMP3*5A nor APOE 4. In conclusion, our finding suggests that the MMP3 gene, especially together with APOE 4, may contribute to the development of AD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.neulet.2004.06.027 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!